Process Development bridges the distance between the research bench and GMP manufacturing for clinical trials. It defines a set of specific objectives to ensure the production of a protein drug will be scalable, reproducible and cost-effective when manufactured under cGMP regulations.
Collectively, Paragon’s upstream and downstream scientists and engineers currently produce and purify 75 to 150 individual proteins per year.